The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The decline in cancer incidence among men and increase among women has narrowed the male‐to-female cancer incidence rate ratio from a peak of 1.6 in 1992 to 1.1 in 2021. In people aged 50-64 years, ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

All types of birth control evaluated were associated with an increased risk of any cancer, and most types of birth control were associated with an increased risk of breast cancer. Note: This ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic ...

The variability in levels of decision regret underscores the complexity of treatment decisions and the need for individualized patient support. Decision regret was a significant concern for women ...

In 37% of cases, patients said the doctor had little time to discuss patient-identified information. US cancer patients have reported positive and negative experiences when sharing patient ...

AVO therapy offered sustained remission and undetectable MRD in patients with TP53 aberrations. Combination therapy with acalabrutinib, venetoclax, and obinutuzumab (AVO) is found to be highly ...

Median time to correct treatment significantly shorter for mpMRI-staged versus transurethral resection of bladder cancer-staged care. HealthDay News — Incorporating multiparametric magnetic ...

Source: Getty Images This review discusses the effects of social isolation and loneliness on quality of life and outcomes for patients with cancer. In a 2023 systematic review focused on young ...

The cumulative incidence of first CRB was 9.8% at 6 months, 16.6% at 12 months, and 23.9% at 24 months. Patients with cancer demonstrated an increased risk of clinically relevant bleeding (CRB ...

The median overall survival was 32 months in patients who received adjuvant chemotherapy and 26 months in patients who did not. Adjuvant multi-agent chemotherapy can improve overall survival (OS ...